|
|
Understanding role of circadian disruption in pathogenesis of MS |
| 1R01NS123532-01A1 |
|
NINDS |
2022 |
|
|
Exploring Akkermansia Genomic and Functional Diversity in Neurologic Diseases |
| 1R21NS126866-01 |
|
NINDS |
2022 |
|
|
Parkinsons disease scalable iPSC autologous cell therapy |
| 3U01NS109463-03S1 |
|
NINDS |
2022 |
|
|
Parkinsons disease scalable iPSC autologous cell therapy |
| 3U01NS109463-03S1 |
|
NINDS |
2022 |
|
|
Defining the role of B cells in modulating CNS inflammation in multiple sclerosis |
| 5F31NS117085-03 |
|
NINDS |
2022 |
|
|
Ethnicity-associated, differential CNS demyelinating autoimmune disease severity: reconciling identity, ancestry and neurotoxic antibody response |
| 5K22NS123508-02 |
|
NINDS |
2022 |
|
|
TMEM106B in neurodegenerative disease |
| 5R01NS082265-08 |
|
NINDS |
2022 |
|
|
Autoimmune features of neurodegenerative disorders |
| 5R01NS095435-05 |
|
NINDS |
2022 |
|
|
Contribution of plasmablasts in the conversion of transverse myelitis to multiple sclerosis |
| 5R01NS102417-05 |
|
NINDS |
2022 |
|
|
Neurovascular Effects of Dopamine Replacement Therapy in Parkinsons Disease |
| 5R01NS105979-04 |
|
NINDS |
2022 |